103
Participants
Start Date
June 4, 2020
Primary Completion Date
February 4, 2026
Study Completion Date
February 4, 2031
Atezolizumab
1200mg IV every 3 weeks for 4 months
SBRT
3 to 5 fractions depending on tumor size
RECRUITING
Institut Bergonié, Bordeaux
NOT_YET_RECRUITING
Centre François BACLESSE, Caen
NOT_YET_RECRUITING
Centre Georges François LECLERC, Dijon
NOT_YET_RECRUITING
Centre Oscar LAMBRET, Lille
NOT_YET_RECRUITING
Centre Léon BERARD, Lyon
ACTIVE_NOT_RECRUITING
AP-HM CHU La Timone, Marseille
NOT_YET_RECRUITING
Institut Paoli CALMETTES, Marseille
RECRUITING
Institut de cancérologie de Montpellier, Montpellier
RECRUITING
Centre Antoine LACASSAGNE, Nice
NOT_YET_RECRUITING
APHP La Pitié, Paris
ACTIVE_NOT_RECRUITING
CHU de Poitiers, Poitiers
NOT_YET_RECRUITING
Centre Eugene MARQUIS, Rennes
NOT_YET_RECRUITING
Centre Henri BECQUEREL, Rouen
RECRUITING
Institut de cancérologie Strasbourg Europe, Strasbourg
NOT_YET_RECRUITING
Institut Claudius REGAUD, Toulouse
NOT_YET_RECRUITING
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
NOT_YET_RECRUITING
Institut Gustave ROUSSY, Villejuif
Centre Hospitalier Universitaire de Caen
OTHER
Roche Pharma AG
INDUSTRY
Centre Antoine Lacassagne
OTHER